Exclusive New Interview Released with Biontech RNA Pharmaceuticals Prior to Keynote Address on RNA Vaccines for Cancer
SMi are delighted to have Dr. Mustafa Diken from Biontech RNA Pharmaceuticals GmbH, present at the 5th Annual Cancer Vaccines Conference when it returns to London on 21st-222nd September 2016.
London, United Kingdom, June 29, 2016 --(PR.com)-- Dr. Mustafa Diken is the Deputy Vice President Immunotherapies and Preclinical Research for Biontech RNA Pharmaceuticals GmbH. His research mainly focuses on the development of novel cancer vaccines based on antigen-encoding messenger RNA (mRNA) and the elucidation of immunomodulatory mechanisms for cancer immunotherapy. His other scientific interests include the use of non-invasive in vivo bioluminescence and fluorescence imaging techniques for preclinical testing of cancer vaccines.*
In the lead-up to the event, SMi group caught up with Dr. Diken to discuss some of the biggest challenges he sees within the cancer vaccines field today.
When asked what he believes are the most difficult challenges he believes cancer vaccines face today, he said, “One of the major challenges is the efficient priming of CD8 as well as CD4 T cells. For this purpose, it is of great importance to provide sufficient co-stimulation to the antigen presenting cells. Moreover, the antigen itself should efficiently be delivered to the antigen presenting cells along with a proper adjuvant which potentiates the T cell priming capabilities of them.”
When asked about what area of cancer vaccine research is seeing the most positive development today Dr. Dicken answered, “RNA based vaccines shows great promise in the recent years. Independent of the vaccine format, individualized vaccines comprising of patient specific mutated neoantigens are very attractive.”
The entire interview is available to read in the event download centre at:
www.cancervaccinesevent.com/prcom
5th Annual Cancer Vaccines Conference
21st-22nd September 2016
Holiday Inn Kensington Forum, London, UK
www.cancervaccinesevent.com/prcom
Proudly Sponsored by: Abzena and Northwest Biotherapeutics
Contact Information:
For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
To register for the conference, visit www.cancervaccinesevent.com/prcom
Tel: +44 (0)20 7827 6093 / Email: mapps@smi-online.co.uk
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 /
Email: amalick@smi-online.co.uk
*Source: http://biontech.de/about/management-team/dr-mustafa-diken/
About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
In the lead-up to the event, SMi group caught up with Dr. Diken to discuss some of the biggest challenges he sees within the cancer vaccines field today.
When asked what he believes are the most difficult challenges he believes cancer vaccines face today, he said, “One of the major challenges is the efficient priming of CD8 as well as CD4 T cells. For this purpose, it is of great importance to provide sufficient co-stimulation to the antigen presenting cells. Moreover, the antigen itself should efficiently be delivered to the antigen presenting cells along with a proper adjuvant which potentiates the T cell priming capabilities of them.”
When asked about what area of cancer vaccine research is seeing the most positive development today Dr. Dicken answered, “RNA based vaccines shows great promise in the recent years. Independent of the vaccine format, individualized vaccines comprising of patient specific mutated neoantigens are very attractive.”
The entire interview is available to read in the event download centre at:
www.cancervaccinesevent.com/prcom
5th Annual Cancer Vaccines Conference
21st-22nd September 2016
Holiday Inn Kensington Forum, London, UK
www.cancervaccinesevent.com/prcom
Proudly Sponsored by: Abzena and Northwest Biotherapeutics
Contact Information:
For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
To register for the conference, visit www.cancervaccinesevent.com/prcom
Tel: +44 (0)20 7827 6093 / Email: mapps@smi-online.co.uk
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 /
Email: amalick@smi-online.co.uk
*Source: http://biontech.de/about/management-team/dr-mustafa-diken/
About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Teri Arri
www.smi-online.co.uk
www.cancervaccines.co.uk/prcom
Teri Arri
www.smi-online.co.uk
www.cancervaccines.co.uk/prcom
Contact
Categories